CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex
Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the
completion of its public offering of 9,100,000 shares of common stock. The
gross proceeds, before commissions and expenses, of the public offering are
$300.3 million.
Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as the sole
book-runner, Morgan Stanley & Co. Incorporated acted as joint lead manager
and UBS Securities LLC acted as co-manager in this offering.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws
of any such state. A shelf registration statement relating to the shares of
common stock has been filed with the Securities and Exchange Commission.
This offering was made only by means of a prospectus, including a
prospectus supplement, forming a part of this registration statement. A
copy of the prospectus can be obtained from Merrill Lynch's prospectus
department, at 4 World Financial Center, New York, NY 10080, 212-449-1000.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is focused on viral diseases,
inflammation, autoimmune diseases, cancer, pain and bacterial infection.
Vertex co-discovered the HIV protease inhibitor, Lexiva, with
GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com
Vertex Contacts:
Lynne H. Brum, VP, Strategic Communications, (617) 444-6614
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com/
http://www.prnewswire.com/comp/938395.html /
CONTACT:
Lynne H. Brum, VP, Strategic Communications,
+1-617-444-6614, or Michael Partridge, Director, Corporate
Communications, +1-617-444-6108, or Lora Pike, Manager, Investor
Relations, +1-617-444-6755, all of Vertex Pharmaceuticals
|
